Library
Celyad Outlines Key 2019 Priorities Including the Acceleration of the CYAD-01 Program in r/r AML and MDS
Celyad Outlines Key 2019 Priorities Including the Acceleration of the CYAD-01 Program in r/r AML and MDS
Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting
Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting
Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Acute Myeloid Leukemia
Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Acute Myeloid Leukemia
Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candidate, CYAD-101
Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candidate, CYAD-101
Celyad Announces Third Quarter 2018 Business Update
Celyad Announces Third Quarter 2018 Business Update
Celyad to Participate at Upcoming Healthcare Conferences
Celyad to Participate at Upcoming Healthcare Conferences
Endogenous DAP10 provides optimal co‐stimulation for NKG2D‐based CARs
Endogenous DAP10 provides optimal co‐stimulation for NKG2D‐based CARs
Generating Allogeneic CAR T cells without Gene Editing
Generating Allogeneic CAR T cells without Gene Editing
Functional screening of different anti-B7H6 CAR designs
Functional screening of different anti-B7H6 CAR designs
Differential effects of target ligands upon NKG2D CAR T cell activation
Differential effects of target ligands upon NKG2D CAR T cell activation
Overcoming target‐driven fratricide for CAR‐T cell therapy
Overcoming target‐driven fratricide for CAR‐T cell therapy